AZN Stock Chart & Stats
kr1671.00
kr22.50(1.35%)
At close: 4:00 PM EDT
kr1671.00
kr22.50(1.35%)
Day’s Range― - ―
52-Week Rangekr1,365.00 - kr1,925.50
Previous CloseN/A
Volume589.63K
Average Volume (3M)318.32K
Market Cap
kr2.52T
Enterprise Valuekr240.56K
Total Cash (Recent Filing)kr4.99B
Total Debt (Recent Filing)kr32.41B
Price to Earnings (P/E)25.3
Beta0.55
Next Earnings
Oct 30, 2026EPS Estimate
25.14Next Dividend Ex-DateN/A
Dividend Yield1.79%
Share Statistics
EPS (TTM)6.72
Shares Outstanding1,551,024,500
10 Day Avg. Volume277,397
30 Day Avg. Volume318,320
Financial Highlights & Ratios
PEG Ratio0.58
Price to Book (P/B)5.91
Price to Sales (P/S)4.90
P/FCF Ratio33.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr2,097.33Price Target Upside25.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)1.32
Revenue Forecast (FY)kr8.13B
Bulls Say, Bears Say
Bulls Say
High Profitability & MarginsSustained high gross and net margins indicate durable earnings power across AstraZeneca's branded portfolio. Strong margins provide recurring cash to fund R&D, launches, and shareholder returns, insulating returns against pricing pressure and enabling reinvestment for multi-year growth.
Large Late‑Stage Pipeline & ApprovalsA deep late‑stage pipeline with multiple positive readouts and new molecular entities materially increases medium‑term commercial optionality. Multiple NMEs and approvals support product replacement for LOE and underpin multi‑year revenue growth and therapeutic leadership, especially in oncology and respiratory.
Strong Cash GenerationRobust operating and free cash flow create durable capacity for R&D funding, capital expenditure, dividends and selective M&A. Predictable cash generation improves capital allocation flexibility and helps service debt, supporting the company's strategic investments over the next 2–6 months and beyond.
Bears Say
Sizeable Debt & Rising LeverageMaterial absolute debt and a recent uptick in leverage reduce financial flexibility if macro rates remain higher or earnings slow. Higher interest and refinancing needs can constrain capital for launches or BD, making sustained cash generation and debt reduction essential to preserve strategic optionality.
Loss‑of‑Exclusivity & China Pricing PressureLOE for major products and structural pricing mechanisms (volume‑based procurement, VBP) in China are eroding a portion of the revenue base. These durable headwinds force reliance on pipeline replacements and can compress growth and margins until new launches scale.
Clinical Trial Setbacks & Execution RiskHigh reliance on late‑stage trials creates binary downside: failed pivotal trials reduce expected future sales and can delay regulatory timelines. Recent significant misses underscore development execution risk and highlight that pipeline success is not guaranteed, affecting medium‑term revenue visibility.
AstraZeneca News
AZN FAQ
What was AstraZeneca PLC’s price range in the past 12 months?
AstraZeneca PLC lowest stock price was kr1365.00 and its highest was kr1925.50 in the past 12 months.
What is AstraZeneca PLC’s market cap?
AstraZeneca PLC’s market cap is kr2.52T.
When is AstraZeneca PLC’s upcoming earnings report date?
AstraZeneca PLC’s upcoming earnings report date is Oct 30, 2026 which is in 89 days.
How were AstraZeneca PLC’s earnings last quarter?
AstraZeneca PLC released its earnings results on Jul 27, 2026. The company reported kr25.107 earnings per share for the quarter, beating the consensus estimate of kr23.637 by kr1.47.
Is AstraZeneca PLC overvalued?
According to Wall Street analysts AstraZeneca PLC’s price is currently Undervalued.
Does AstraZeneca PLC pay dividends?
AstraZeneca PLC pays a Semiannually dividend of kr19.538 which represents an annual dividend yield of 1.79%. See more information on AstraZeneca PLC dividends here
What is AstraZeneca PLC’s EPS estimate?
AstraZeneca PLC’s EPS estimate is 25.14.
How many shares outstanding does AstraZeneca PLC have?
AstraZeneca PLC has 1,551,024,500 shares outstanding.
What happened to AstraZeneca PLC’s price movement after its last earnings report?
AstraZeneca PLC reported an EPS of kr25.107 in its last earnings report, beating expectations of kr23.637. Following the earnings report the stock price went up 1.606%.
Which hedge fund is a major shareholder of AstraZeneca PLC?
Currently, no hedge funds are holding shares in SE:AZN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AstraZeneca Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
kr2,097.33 (25.51% Upside)
kr2,097.33 (25.51% Upside)
Blogger Sentiment
Bullish
SE:AZN Sentiment 67%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth kr21.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 94%
Bearish news 6%
Bearish news 6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.45%
12-Months-Change
Fundamentals
Return on Equity
1.79%
Trailing 12-Months
Asset Growth
6.38%
Trailing 12-Months
Company Description
AstraZeneca PLC
AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, key marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascular, renal, and metabolism diseases, the company offers treatments such as Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR. Respiratory and immunology conditions are targeted by products like Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris. Additionally, rare diseases are treated with Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris. The company's product offerings also extend to Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for influenza; Seroquel IR/Seroquel XR for schizophrenia and bipolar disorder; Nexium and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for COVID-19. AstraZeneca serves primary and specialty care physicians globally, leveraging a network of distributors and local representative offices across the United Kingdom, the rest of Europe, the Americas, Asia, Africa, and Australasia. Strategic collaboration forms a vital component of its operations. Partnerships include an agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG for the development and commercialization of NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for transthyretin amyloidosis; Proteros Biostructures GmbH for the joint discovery of novel small molecules targeting hematological cancers; and Sierra Oncology, Inc. for the development and commercialization of AZD5153. Initially incorporated in 1992 as Zeneca Group PLC, the company adopted its current name, AstraZeneca PLC, in April 1999. It is headquartered in Cambridge, United Kingdom.
AZN Stock 12 Month Forecast
Average Price Target
kr2,097.33
▲(25.51% Upside)
Technical Analysis
ConvaTec
―
GlaxoSmithKline
―
Hikma Pharmaceuticals
―
Smith & Nephew
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―